A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease

Launched by MTHERA PHARMA CO., LTD. · Dec 8, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called MT101-5 to see if it is safe, tolerable, and effective for people who have recently been diagnosed with early Parkinson's disease. Parkinson's disease is a condition that affects movement and can cause symptoms like tremors and stiffness. In this study, researchers will compare MT101-5 to a placebo (a pill that looks like the medication but has no active ingredients) to determine how well it works. The trial is currently not recruiting participants.

To be eligible for the study, participants must be between 30 and 79 years old and have been diagnosed with Parkinson's disease for two years or less. They should not be taking any Parkinson's medications, or if they are, they must have been on a stable dose for at least four weeks before joining the study. Participants will need to sign a consent form and agree to follow the study guidelines. Throughout the trial, participants can expect regular check-ups and assessments to ensure their safety and monitor how they respond to the medication. It's important to note that there are some specific criteria that would exclude individuals from joining, such as having certain other health conditions or taking specific medications.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Subjects will be eligible for enrollment in the study only if they meet ALL of the following criteria:
• • 1. Male or female subjects who are between 30 and 79 years old inclusive with a clinical diagnosis of Parkinson's disease as per UK Brain Bank Criteria for two (2) years or less at screening.
• • 2. Hoehn and Yahr I or II at screening.
• • 3. Subjects who are newly diagnosed \& currently not on any Parkinson's disease medication (or) subjects who are on stable doses for at least 4 weeks prior to screening on Amantadine or anticholinergics for treatment of Parkinson's disease (1) Note: Subjects that had anti-parkinsonian medication (including levodopa, dopamine agonists, entacapone and monoamine oxidase-B inhibitors) discontinued at least 60 days prior to screening, e.g., for intolerance, may be considered eligible if all other eligibility requirements are met.
• • 4. Without clinically significant abnormalities in physical exam, neurological exam and laboratory assessments (urine/blood routine, biochemical tests and ECG) which would exclude the subject from the study in the opinion of the Investigator. For aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) the screening levels should be ≤ 2 times upper limit normal.
• • 5. Subject is capable of providing informed consent and is willing to sign the ICF prior to study Screening and agrees to comply with the study protocol requirements.
• • Exclusion Criteria
• Subjects will be eligible for enrollment in the study only if they meet NONE of the following criteria:
• • 1. Subject has an atypical parkinsonian syndrome or secondary parkinsonism (e.g., due to drugs, metabolic neurogenetic disorders, encephalitis, cerebrovascular disease or degenerative disease).
• • 2. Subjects with history of neurosurgical intervention for Parkinson's disease.
• • 3. Subjects who meet the DSM-V criteria at screening for bipolar disorder, major depressive disorder, psychotic disorders, or any other comorbid mental disorders that in the opinion of the Investigator may interfere with study conduct and results interpretation.
• • 4. Subjects with clinical diagnosis of dementia (MMSE score \<24) as determined by the investigator using Mini-Mental State Examination (MMSE).
• • 5. Female subjects who are pregnant or breast feeding.
• • 6. Initiation of any anti-parkinsonian medication (including levodopa, dopamine agonists, entacapone and monoamine oxidase-B inhibitors) for the duration of the trial.
• • 7. Initiation of Amantadine or anticholinergics for newly diagnosed subjects or change in the dosage of Amantadine or anticholinergics during the trial for subjects who were on stable doses for 4 weeks prior to screening.
• • 8. Medical or recreational use of marijuana or THC-containing compounds within 3 months of screening visit and for the duration of the trial.
• • 9. Subjects who used investigational drugs or devices within 60 days prior to screening or investigational biologics within the last 6 months prior to screening.
• • 10. Subjects with a clinically significant medical or surgical condition, including major surgeries within 28 days prior to enrollment.
• • 11. The subject has a known allergy or hypersensitivity to any component of the formulation.
• • 12. The subject has a history of alcohol abuse (defined as an alcohol intake more than 21 units per week) or a history of drug abuse within the 6 months before study drug administration, or a history of substance abuse deemed significant by the investigator. A unit of alcohol is defined as 240 mL of beer, 120 mL of wine, or 1 single shot of spirits.
• • 13. Women of child-bearing age who are sexually active but decline to take proper contraceptive measures during the study period
• • Note: To be eligible for the study, Women of childbearing potential (WOCBP) and Women not of childbearing potential are eligible to participate. Both women of childbearing potential and women of no childbearing potential should use an approved method of birth control and agrees to continue to use this method for the duration of the study (and for 30 days after taking the last dose of investigational product).
• • Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method (WOCBP only), female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner is surgically sterile or 2 years post-menopausal. All male subjects/partners of WOCBP must agree to consistently and correctly use a condom for the duration of the study and for 30 days after taking the study drug. In addition, subjects may not donate ova or donate sperm for the duration of the study and for 30 days after taking the last dose investigational product.